减低剂量与标准预处理方案序贯异基因干细胞移植治疗骨髓增生异常综合征患者:EBMT 前瞻性随机 III 期研究(RICMAC 试验)
该前瞻性、多中心、开放标签、随机 III 期试验由欧洲血液与骨髓移植学会开展,在 18 个中心纳入 129 例骨髓增生异常综合征或继发性急性髓系白血病患者,1:1 随机比较白消安为基础的减低强度预处理(RIC)与清髓性预处理(MAC)。结果显示 RIC 组至少 2 年无复发生存和总生存与 MAC 组相似。
要点
- 129 例 MDS 或继发性 AML 患者随机接受 RIC 或 MAC,移植植入率两组相当。
- RIC 组 1 年非复发死亡率 17%,MAC 组 25%,差异无统计学显著(P = .29)。
- RIC 组 2 年无复发生存 62%、总生存 76%,MAC 组分别为 58% 和 63%。
核心结论
- 该前瞻性随机试验提供证据表明,在 MDS 或继发性急性髓系白血病患者中,RIC 至少可获得与 MAC 相似的 2 年无复发生存和总生存。
研究设计与样本
- 欧洲血液与骨髓移植学会开展的前瞻性、多中心、开放标签、随机 III 期试验,比较白消安为基础的 RIC 与 MAC。
- 共 129 例 MDS 或继发性急性髓系白血病患者从 18 个中心入组,按 1:1 随机分组,并根据供者、年龄和原始细胞计数分层。
主要发现
- 两组植入情况相当。
- 急性移植物抗宿主病 II 至 IV 度累积发生率 RIC 组为 32.3%,MAC 组为 37.5%(P = .35)。
- 慢性移植物抗宿主病累积发生率 RIC 组为 61.6%,MAC 组为 64.7%(P = .76)。
- 1 年非复发死亡累积发生率 RIC 组为 17%(95% CI,8% 至 26%),MAC 组为 25%(95% CI,15% 至 36%)(P = .29)。
- 2 年复发累积发生率 RIC 组为 17%(95% CI,8% 至 26%),MAC 组为 15%(95% CI,6% 至 24%)(P = .6);2 年无复发生存 RIC 组为 62%(95% CI,50% 至 74%),MAC 组为 58%(95% CI,46% 至 71%)(P = .58);2 年总生存 RIC 组为 76%(95% CI,66% 至 87%),MAC 组为 63%(95% CI,51% 至 75%)(P = .08)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative conditioning regimen (MAC) before allogeneic transplantation in patients with myelodysplastic syndrome (MDS) within a randomized trial. Patients and Methods Within the European Society of Blood and Marrow Transplantation, we conducted a prospective, multicenter, open-label, randomized phase III trial that compared a busulfan-based RIC with MAC in patients with MDS or secondary acute myeloid leukemia. A total of 129 patients were enrolled from 18 centers. Patients were randomly assigned in a 1:1 ratio and were stratified according to donor, age, and blast count. Results Engraftment was comparable between both groups. The CI of acute graft-versus-host disease II to IV was 32.3% after RIC and 37.5% after MAC ( P = .35). The CI of chronic graft-versus-host disease was 61.6% after RIC and 64.7% after MAC ( P = .76). The CI of nonrelapse mortality after 1 year was 17% (95% CI, 8% to 26%) after RIC and 25% (95% CI, 15% to 36%) after MAC ( P = .29). The CI of relapse at 2 years was 17% (95% CI, 8% to 26%) after RIC and 15% (95% CI, 6% to 24%) after MAC ( P = .6), which resulted in a 2-year relapse-free survival and overall survival of 62% (95% CI, 50% to 74%) and 76% (95% CI, 66% to 87%), respectively, after RIC, and 58% (95% CI, 46% to 71%) and 63% (95% CI, 51% to 75%), respectively, after MAC ( P = .58 and P = .08, respectively). Conclusion This prospective, randomized trial of the European Society of Blood and Marrow Transplantation provides evidence that RIC resulted in at least a 2-year relapse-free survival and overall survival similar to MAC in patients with MDS or secondary acute myeloid leukemia.
引用
- Kröger N, Iacobelli S, Franke GN, et al. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol. 2017. PMID: 28463633. doi:10.1200/JCO.2016.70.7349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。